Jane Street Group, LLC Akebia Therapeutics, Inc. Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$0.72 - $2.93 $104,760 - $426,315	145,500 Added 782.26%	164,100 $118,000
Q4 2021 Feb 15, 2022	SELL	$2.26 - $3.34 $152,776 - $225,784	-67,600 Reduced 78.42%	18,600 $42,000
Q3 2021 Nov 16, 2021	SELL	$2.35 - $3.88 $75,905 - $125,324	-32,300 Reduced 27.26%	86,200 $248,000
Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $106,974 - $158,760	37,800 Added 46.84%	118,500 $449,000
Q1 2021 May 18, 2021	BUY	$2.92 - $5.06 $48,472 - $83,996	16,600 Added 25.9%	80,700 $273,000
Q4 2020 Feb 17, 2021	SELL	$2.22 - $3.78 $83,916 - $142,884	-37,800 Reduced 37.1%	64,100 $179,000
Q3 2020 Nov 17, 2020	BUY	$2.39 - $13.08 $243,541 - $1.33 Million	101,900 New	101,900 $256,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.